UPDATE: Deutsche Bank Reiterates on Amgen Following Biosimilar Conference
November 20, 2013 at 09:21 AM EST
In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Amgen (NASDAQ: AMGN ), and raised the price target from $138.00 to $142.00. In the report, Deutsche Bank noted, “We attended a biosimilar conference in order to learn more about the OPP'Y for Amgen. We
